Liquid Biopsy Panel for Lung Cancer 11 Gene Test - Book at an Affordable Cost

Smashing the Description

The leading cause of cancer-related mortality in both sexes is lung cancer.Adenocarcinoma, squamous cell carcinoma, and large-cell lung cancer make up the majority of non-small cell lung cancers (NSCLC), which account for around 85% of all lung cancer cases. The high mortality is mostly caused by the aggressiveness of the disease and the fact that the majority of lung tumors are typically discovered at late, inoperable stages of the illness. The best course of treatment for NSCLC patients who have been identified with confined, early-stage illness is still surgical excision with curative intent.

Clinical uses for liquid biopsy

The current gold standard of care for directing treatment choices in advanced patients involves molecular profiling of tumor specimens at diagnosis. Tumor tissue biopsy, however, is an invasive process with a number of drawbacks in clinical practice: it frequently offers insufficient materials, it depicts a single snapshot of the tumor, and it is susceptible to selection bias brought on by tumor heterogeneity. Furthermore, because the majority of diagnostic techniques are intrusive and uncomfortable for patients, it is difficult to frequently obtain tumor tissue specimens to monitor tumor dynamics over time. For the noninvasive evaluation of tumor-specific biomarkers and for a range of clinical and investigative purposes, liquid biopsy has been widely shown to be a feasible substitute for tumor tissue.

Exosomes, tumor-educated platelets (TEP), circulating tumor cells, cell-free tumor DNA (cfDNA), and cell-free tumor RNA (cfRNA) can all be separated from blood as tumor-derived components. (CTCs).

When a biopsy is difficult to collect for logistical or clinical reasons, liquid biopsy makes it easier to find clinically significant tumor mutations from a blood sample:

• Unlike most biopsies, sample quantity and frequency are not constrained.
• Simple, risk-free venipuncture without the need for a difficult technique
• Does not require immediate shipping or cold-chain assistance

When must you get tested?

Cancer patients' care and relapse tracking

During therapy, recognizing secondary acquired resistance mutations

When starting baseline therapy and at regular intervals, keep an eye on patients to gauge their clinical reaction to the medication.

The following are some benefits of this test employing Next-generation Sequencing (NGS) technology:

• High sensitivity and capacity for spotting rare mutations
• NGS, as opposed to RT-PCR, provides the benefit of multi-gene profiling in a single test that includes an exon spanning the HOTSPOT mutation and requires a little amount of DNA without sacrificing sensitivity and specificity.
• Less time for turnaround